Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial - Powles, T; van der Heijden, MS; Castellano, D (Lancet Oncol, 2020)
et al.